Capsule system
AssigneeAllergan, Inc.
InventorsBruce A. Firestone, Thao T. Tran
Life of this patent
Estimating the term…
Abstract
A capsule system for oral delivery of an active agent having low aqueous solubility generally includes, in combination with the active agent, a vehicle for preventing initial active agent dissolution within the gastrointestinal tract and an emulsifier for promoting self-emulsification of the active agent and vehicle in the gastrointestinal tract. A capsule shell is provided for encapsulating the active agent, vehicle and emulsifier with the shell being formulated to open upon ingestion into the gastrointestinal tract and release the active agent and vehicle.
Claims9
A method for enabling delivery of Tazarotene, the method comprising the steps of:
- manufacturing a fill formulation by dissolving Caprylic/Capric Triglyceride (CCT) butylated hydroxytoluene and thereafter dissolving the Tazarotene thereinto;
- adding Polysorbate 80 and Sorbiton Monooleate to the CCT, butylated hydroxyanide and Tazarotene to form a bulk solution;
- mixing the bulk solution until homogeneous;
- and
- encapsulating the homogeneous bulk solution into a capsule.
A method for enabling delivery of an active agent having low aqueous solubility, the method comprising the steps of:
- providing an active retinoid agent having low aqueous solubility consisting of Tazarotene;
- dissolving the active agent in a vehicle in order to eliminate initial active agent dissolution within a gastrointestinal tract;
- incorporating an emulsifier into the vehicle in order to promote subsequent self-emulsification of the active agent and vehicle in the gastrointestinal tract;
- encapsulating the active agent, vehicle and emulsifier with a capsule shell formulated to open upon ingestion into said gastrointestinal tract;
- and
- drying the capsule shell to obtain a selected hardness.
A capsule system for oral delivery of an active agent having low aqueous solubility, said capsule system comprising:
- an active retinoid agent having low aqueous solubility consisting of Tazarotene;
- vehicle means for initially dissolving the active agent;
- emulsifier means for promoting self-emulsification of the active agent and vehicle means in the gastrointestinal tract;
- and
- capsule shell means for encapsulating the active agent, vehicle means, and emulsifier means as a non-emulsified, homogeneous mixture, said capsule shell means having a selected hardness and formulated to open upon ingestion into said gastrointestinal tract and release the mixture, thus enabling self-emulsification of the vehicle means, with the active agent dissolved therein in the gastrointestinal tract.
Dependencies are inferred from the claim text.